<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/17CC1B1E-CD59-46DB-B924-5C91D269A68F"><gtr:id>17CC1B1E-CD59-46DB-B924-5C91D269A68F</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:otherNames>K</gtr:otherNames><gtr:surname>Mercer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701380"><gtr:id>7D981283-B0E4-4C04-B71F-E9A6F5E40628</gtr:id><gtr:title>Safety of longterm anti-TNF use, with respect to malignancy, in a national cohort of people with rheumatoid arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701380</gtr:grantReference><gtr:abstractText>Cancer is more common in people who have rheumatoid arthritis (RA), a painful disease of the joints. This is especially true for skin and lung cancer and lymphoma, a cancer of the immune system. This may be due to persistent inflammation. A new drug, called anti-TNF, controls this inflammation and may therefore, reduce the risk of cancer. However, there is a risk that this drug may actually cause cancer because it blocks the action of TNF, a protein which protects the body from cancer. Therefore, many physicians and patients are nervous about prescribing this drug. Using data from people with RA who have enrolled in a long-term study of anti-TNF use, I will measure inflammation as well as the duration of treatment with anti-TNF. I will then use statistical tests to estimate whether the drug or the inflammation is responsible for causing any cancers that develop. The results will inform doctors better on the use of these drugs. Although this study is specific to cancer and arthritis, the skills acquired will be applicable to other drugs and other diseases where a drug may have dual actions in the body.</gtr:abstractText><gtr:technicalSummary>Background: Rheumatoid arthritis (RA) is associated with an increased risk of certain malignancies, including lymphoproliferative malignancies (LPM), skin and lung cancers. The increased risk of LPM may relate in part to chronic immune stimulation. Drugs which block the action of tumour necrosis factor (anti-TNF) are very effective in controlling this inflammation. However, as a cytokine of the innate immune system, TNF plays a critical role in tumour surveillance and therefore, there is a concern that blockade of this cytokine may increase further this risk of malignancy. Alternatively, patients who receive anti-TNF therapies, by way of improved disease control, may ultimately have a lower risk of malignancy.
Aim: To develop an expertise in epidemiological research methods, with a particular focus on long-term malignancy risk in RA patients treated with anti-TNF drugs.
Research Methods: The incidence of malignancy in an anti-TNF treated RA cohort will be measured, and the relative risk of malignancy compared to a non-biologic disease modifying anti-rheumatic drug (DMARD) cohort will be determined. Using both prospective data modelling as well as undertaking a smaller nested case-control study, the influence of cumulative disease activity, and in particular, disease control on the risk of LPM and other malignancies will be determined. The importance of a past diagnosis of malignancy on recurrent disease will also be addressed. Data for this project will be obtained from the large British Society for Rheumatology Biologics Register (BSRBR), a longitudinal observational study of patients receiving anti-TNF therapies for RA. To date, over 11000 anti-TNF patients have been recruited to this study and over 3100 DMARD control patients. In addition to the data held in this register, further disease and histopathology data will be obtained, either by questionnaire or where appropriate, individual case note review, in patients who develop a malignancy during the course of study to address further the association between inflammation and LPM.
Medical Opportunities: These results will inform the wider medical and patient communities on the long-term cancer risk of anti-TNF use. If the results show an increase in malignancy risk, use of these drugs may need to be limited. Alternatively, if a decrease is seen, the results may support the wider and earlier use of these drugs in RA, which currently have tight prescribing guidelines.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>174432</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day at unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>213A4112-D27A-4666-BD85-1CC033571363</gtr:id><gtr:impact>75 members of the public, largely Arthritis Research UK supporters and patients, attended the Arthritis Research Uk Epidemiology Unit. Communication was via poster and informal conversation.

We received positive feedback, particularly commending the use of layman terms</gtr:impact><gtr:outcomeId>pA6Zr7yDknF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press conference, Philidelphia</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>2383CA41-889C-43B9-964E-BFABA3034354</gtr:id><gtr:impact>Press conference regarding research that was picked up by US medical and general press.

I was on mat leave at the time, this was disseminated by a colleague on my behalf</gtr:impact><gtr:outcomeId>bXdVCBkd5GG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSRBR newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>B88A085C-A7A4-4805-AE6A-F1F95B1BAB69</gtr:id><gtr:impact>6 monthly newsletter that increases awareness of th estudy's progress and results.

Increased awareness of the study has led to a high uptake of our advice line (email) being used</gtr:impact><gtr:outcomeId>JbNK9aiWbFE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press conference, Chicago</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>2EFA64BF-0C7E-4042-AEDB-30A8FCF80463</gtr:id><gtr:impact>Planned for 7 nov 2011

tbc</gtr:impact><gtr:outcomeId>YTwsGTopqXi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1650C973-B487-4805-8E69-F4BE6A576F3A</gtr:id><gtr:title>Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_13461_21_23238979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81A30274-46D8-4B9B-8D31-233025A10D7D</gtr:id><gtr:title>The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef1c2730892a711bbdd8bb584516ce56"><gtr:id>ef1c2730892a711bbdd8bb584516ce56</gtr:id><gtr:otherNames>Z?vada J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13461_21_23644671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC32F0F-872A-4EE5-B0CA-AFB578BD0CCB</gtr:id><gtr:title>Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1fb87fcd35e0f57e8cbc96ade3f7db3"><gtr:id>d1fb87fcd35e0f57e8cbc96ade3f7db3</gtr:id><gtr:otherNames>Dixon WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>gYTC5478YH1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7444392C-3B7A-4786-A6AC-C09FCE6FC371</gtr:id><gtr:title>Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>Jjmw5zXbNs3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0C62554-6956-4C65-96E2-86B0469A8DE2</gtr:id><gtr:title>Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13461_21_22843488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A489387B-A1F2-4E0B-BEDD-301C68807908</gtr:id><gtr:title>Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13461_21_22532633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFA75EBD-6041-4AF8-929B-4D562C0D4124</gtr:id><gtr:title>Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/436a29d0a6a0bbb165e0802eaf6e975f"><gtr:id>436a29d0a6a0bbb165e0802eaf6e975f</gtr:id><gtr:otherNames>Low AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>56f3be362e8421.50844895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A483406-1AFE-4CE2-96D7-39C8FEBF4589</gtr:id><gtr:title>Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd89c3abad19c0472cdedb8fed78261b"><gtr:id>dd89c3abad19c0472cdedb8fed78261b</gtr:id><gtr:otherNames>Galloway JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13461_21_21784730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B943178-C9B8-4901-9E04-640324B01084</gtr:id><gtr:title>The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13461_21_22241900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A82212E-D1AB-49F5-8C7C-22226FB88E05</gtr:id><gtr:title>Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14df51807ce56ce07ec9af11c559a1eb"><gtr:id>14df51807ce56ce07ec9af11c559a1eb</gtr:id><gtr:otherNames>Mercer LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>545a905368d871.46738176</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701380</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>